Physician profile
James Moreci
NPI 1982677183
$3,964.80
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $535 · 2021: $1,083 · 2022: $802 · 2023: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $150.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $556.91 | 2019-2022 | |
| Janssen Biotech, INC. | $492.86 | 2019-2022 | |
| Abbvie INC. | $340.52 | 2019-2022 | |
| Antares Pharma, INC. | $336.90 | 2019-2022 | |
| Abbott Laboratories | $253.68 | 2021-2023 | Freestyle Libre 3 |
| Novo Nordisk INC | $244.78 | 2019-2022 | |
| Ucb, INC. | $216.62 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $182.99 | 2019-2020 | |
| Lilly USA, LLC | $171.22 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $141.27 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $125.14 | 2019-2022 | |
| Amarin Pharma, INC. | $113.93 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $101.72 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $88.16 | 2020-2022 | |
| Radius Health, INC. | $58.02 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55.07 | 2019-2022 | |
| Mannkind Corporation | $47.33 | 2019-2021 | |
| Pacira Therapeutics, INC. | $43.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $42.06 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $41.36 | 2019-2021 | |
| Daiichi Sankyo INC. | $34.42 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $32.08 | 2019 | |
| Astellas Pharma US INC | $29.31 | 2020-2021 | |
| Dexcom, INC. | $26.61 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $25.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.64 | 2020 | |
| Allergan, INC. | $23.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.96 | 2022 | |
| Sumitomo Pharma America, INC. | $19.34 | 2023 | Gemtesa |
| Regeneron Healthcare Solutions, INC. | $18.79 | 2019 | |
| Eisai INC. | $14.67 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.53 | 2019 | |
| Insulet Corporation | $12.54 | 2022 | |
| Esperion Therapeutics, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Moreci listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.